The Patent Finder

Substituted Quinazolines as Inhibitors of Kras G12C

Araxes Pharma LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 62/052,366, filed Sep 18, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 9,840,516Substituted Quinazolines as Inhibitors of Kras G12C
In force
 · High confidence
UsedRemaining
Araxes Pharma LLCIn forceHigh confidence
US 10,370,386Substituted Quinolines as Inhibitors of Kras G12C
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 10,927,125Substituted Cinnolines as Inhibitors of Kras G12C
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 11,878,985Substituted Quinazolines as Inhibitors of Kras G12C
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 12,234,244Substituted Piperazines as Inhibitors of Kras G12C
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
Application 18/178,452Substituted Piperazines as Inhibitors of Kras G12C
Abandoned
Abandoned Jul 1, 2024
Araxes Pharma LLCAbandonedAbandoned Jul 1, 2024
Application 18/183,870Substituted Piperazines as Inhibitors of Kras G12C
Abandoned
Abandoned Jul 1, 2024
Araxes Pharma LLCAbandonedAbandoned Jul 1, 2024
Application 18/416,739Substituted Piperazines as Inhibitors of Kras G12C
Pending
Not granted
Araxes Pharma LLCPendingNot granted
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Araxes Pharma LLC.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited